Doxycycline hyclate 是一种具有口服活性的四环素抗生素，是广谱的金属蛋白酶 (MMP) 抑制剂，具有抗菌活性和抗癌细胞增殖活性。
| 生物活性 | Doxycycline hyclate, anantibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1]. Doxycycline hyclate shows antibacterial activity and anti-cancer cell proliferation activity[1][2][3][4][5]. |
| IC50& Target | |
体外研究
(In Vitro) | Doxycycline hyclate (0.01-10 μg/mL, 4 d) affects growth of glioma cells only under high concentrations[2].
Doxycycline hyclate (0.01-10 μg/mL, 24 h) decreases MT-CO1 protein content with concentrations of 1 μg/mL and higher in SVG cells[2].
Doxycycline hyclate (100 ng/mL, 1 μg/mL; 24 h) reduces proliferation of human cell lines[4].
Doxycycline hyclate (0-250 μM, 72 h) inhibits cell viability of breast cancer cells[5].
Cell Viability Assay[2] | Cell Line: | LNT-229, G55, and U343 glioma cells | | Concentration: | 0.01, 0.1, 1 or 10 μg/mL | | Incubation Time: | 4 days | | Result: | Affected growth of glioma cells only under high concentrations (10 μg/mL). |
Cell Viability Assay[2] | Cell Line: | SVG cells | | Concentration: | 0.01, 0.1, 1 or 10 μg/mL | | Incubation Time: | 24 hours | | Result: | Decreaseed MT-CO1 protein content with concentrations of 1 μg/mL and higher. |
Cell Proliferation Assay[4] | Cell Line: | MCF 12A, 293T cells | | Concentration: | 100 ng/mL, 1 μg/mL | | Incubation Time: | 96 hours | | Result: | Caused reduced proliferation of MCF 12A and 293T cells at 1 μg/mL. |
Cell Viability Assay[5] | Cell Line: | MCF-7, MDA-MB-468 cells | | Concentration: | 0-250 μM | | Incubation Time: | 72 hours | | Result: | Inhibited breast cancer cells in a dose-dependent manner with IC50values for MCF-7 and MDA-MB-468 of 11.39 μM and 7.13 μM respectively. |
|
体内研究
(In Vivo) | Doxycycline hyclate (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner[3].
| Animal Model: | 6-month-old female Heterozygous Col3a1-deficient (HT) mice[3] | | Dosage: | 200 or 800 mg/kg | | Administration: | Oral gavage; 200 or 800 mg/kg; once daily; 3 months | | Result: | Reduced MMP-9 activity in a dose-dependent manner. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | 多西环素盐酸盐半乙醇半水合物；强力霉素盐酸盐半乙醇半水合物 |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| 溶解性数据 | In Vitro: DMSO : 240 mg/mL(467.89 mM;Need ultrasonic) H2O : 125 mg/mL(243.69 mM;Need ultrasonic) 配制储备液 | 1 mM | 1.9495 mL | 9.7477 mL | 19.4955 mL | | 5 mM | 0.3899 mL | 1.9495 mL | 3.8991 mL | | 10 mM | 0.1950 mL | 0.9748 mL | 1.9495 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 20 mg/mL (38.99 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂： 5% DMSO 40%PEG300 5%Tween-80 50% saline Solubility: ≥ 3 mg/mL (5.85 mM); Clear solution 3. 请依序添加每种溶剂： 5% DMSO 95% (20%SBE-β-CDin saline) Solubility: ≥ 3 mg/mL (5.85 mM); Clear solution
*以上所有助溶剂都可在本网站选购。 |
m.cnreagent.com